132 related articles for article (PubMed ID: 34093867)
1. Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.
Bhattarai N; Wang J; Nguyen D; Yang X; Helmers L; Paruch J; Li L; Zhang Y; Meng K; Wang A; Jayawickramarajah J; Wang B; Zeng S; Lu H
Theranostics; 2021; 11(14):7005-7017. PubMed ID: 34093867
[TBL] [Abstract][Full Text] [Related]
2. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth.
Zhang Q; Ding D; Zeng SX; Ye QZ; Lu H
PLoS One; 2012; 7(10):e46294. PubMed ID: 23115626
[TBL] [Abstract][Full Text] [Related]
3. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.
Zhang Q; Zeng SX; Zhang Y; Zhang Y; Ding D; Ye Q; Meroueh SO; Lu H
EMBO Mol Med; 2012 Apr; 4(4):298-312. PubMed ID: 22331558
[TBL] [Abstract][Full Text] [Related]
4. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.
Zhang Y; Zhang Q; Zeng SX; Hao Q; Lu H
Neoplasia; 2013 May; 15(5):523-34. PubMed ID: 23633924
[TBL] [Abstract][Full Text] [Related]
5. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
6. Global effect of inauhzin on human p53-responsive transcriptome.
Liao JM; Zeng SX; Zhou X; Lu H
PLoS One; 2012; 7(12):e52172. PubMed ID: 23284922
[TBL] [Abstract][Full Text] [Related]
7. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.
Zhang Y; Zhang Q; Zeng SX; Zhang Y; Mayo LD; Lu H
Cancer Biol Ther; 2012 Aug; 13(10):915-24. PubMed ID: 22785205
[TBL] [Abstract][Full Text] [Related]
8. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress.
Zhang Q; Zhou X; Wu R; Mosley A; Zeng SX; Xing Z; Lu H
Elife; 2014 Oct; 3():. PubMed ID: 25347121
[TBL] [Abstract][Full Text] [Related]
9. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
Chen S; Ren Y; Duan P
Biomed Pharmacother; 2020 Sep; 129():110371. PubMed ID: 32563984
[TBL] [Abstract][Full Text] [Related]
10. Calcium-oxidative stress signaling axis and casein kinase 1α mediate eryptosis and hemolysis elicited by novel p53 agonist inauhzin.
Alfhili MA; Alsalmi E; Aljedai A; Alsughayyir J; Abudawood M; Basudan AM
J Chemother; 2022 Jul; 34(4):247-257. PubMed ID: 34410893
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
12. Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice.
Zhang Q; Zeng SX; Lu H
Toxicol Rep; 2015; 2():546-554. PubMed ID: 26167454
[TBL] [Abstract][Full Text] [Related]
13. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
14. Selective targeting p53
Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
[TBL] [Abstract][Full Text] [Related]
15. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
16. Awakening p53
Bian Z; Yan J; Wang S; Li Y; Guo Y; Ma B; Guo H; Lei Z; Yin C; Zhou Y; Liu M; Tao K; Hou P; He W
Theranostics; 2018; 8(19):5320-5335. PubMed ID: 30555549
[TBL] [Abstract][Full Text] [Related]
17. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.
Guo J; Yang Y; Yang Y; Linghu E; Zhan Q; Brock MV; Herman JG; Zhang B; Guo M
Oncotarget; 2015 Feb; 6(6):4202-13. PubMed ID: 25638156
[TBL] [Abstract][Full Text] [Related]
18. TFIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene.
Liao JM; Cao B; Deng J; Zhou X; Strong M; Zeng S; Xiong J; Flemington E; Lu H
Sci Rep; 2016 Mar; 6():23542. PubMed ID: 27005522
[TBL] [Abstract][Full Text] [Related]
19. Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells.
Huang G; Zang B; Wang X; Liu G; Zhao J
Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):981-7. PubMed ID: 26525950
[TBL] [Abstract][Full Text] [Related]
20. An Anti-Cancer Peptide LVTX-8 Inhibits the Proliferation and Migration of Lung Tumor Cells by Regulating Causal Genes' Expression in p53-Related Pathways.
Zhang P; Yan Y; Wang J; Dong X; Zhang G; Zeng Y; Liu Z
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32498425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
